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Abstract
Objective—To investigate the interaction of treatment-related hemodynamic changes with
genotype status for Synaptosomal associated protein 25 (SNAP-25) gene in participants with
attention deficit hyperactivity disorder (ADHD) on and off single dose short-acting
methylphenidate treatment with functional near-infrared spectroscopy (fNIRS).
Method—A total of 15 right-handed adults and 16 right-handed children with DSM-IV diagnosis
of ADHD were evaluated. Ten milligrams of short-acting methylphenidate was administered in a
crossover design.
Results—Participants with SNAP-25 DdeI T/T genotype had decreased right deoxyhemoglobin
([HHb]) with treatment. SNAP-25 MnlI genotype was also associated with right deoxyhemoglobin
([HbO2]) and [HHb] changes as well as left [HHb] change. When the combinations of these
genotypes were taken into account, the participants with [DdeI C/C or T/C and MnlI G/G or T/G]
genotype had increased right [HHb] with MPH use whereas the participants with [DdeI T/T and
MnlI T/T] or [DdeI T/T and MnlI G/G or T/G] genotypes had decreased right prefrontal [HHb].
Conclusions—These results suggested that SNAP-25 polymorphism might be associated with
methylphenidate induced brain hemodynamic changes in ADHD participants.
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ADHD is one of the most common neurodevelopmental disorders of childhood. There is an
increasing convergence of results demonstrating both structural and functional brain
differences in participants with ADHD. Structural and functional neuroimaging studies have
shown abnormalities of the whole brain, frontal lobes, basal ganglia, corpus callosum,
parietal lobes, temporal cortex, and cerebellar vermis (Bush, Valera, & Seidman, 2005;
Seidman, Valera, & Makris, 2005).
Numerous genetic alterations have been reported in participants with ADHD (Faraone et al.,
2005). Most of the proposed genes are associated with the dopaminergic system. SNAP-25
is a presynaptic plasma membrane protein that plays an important role in the synaptic
vesicle membrane docking and fusion (Zhao, Hashida, Takahashi, & Sakaki, 1994).
SNAP-25 constitutes complexes with synaptobrevin on synaptic vesicles and syntaxin on
plasma membrane that are related with neuronal exocytosis that is triggered by calcium (Hu
et al., 2003). The transmission of SNAP-25 alleles in ADHD has been investigated and these
studies reported an increased transmission of DdeI allele (Brophy et al., 2002; Kustanovich
et al., 2003), of a haplotype (made of allele 1 of MnlI and allele 2 of the DdeI; Barr et al.,
2000), and micro-satellites in ADHD participants (Mill et al., 2002, 2004). Meta-analysis of
these studies showed a significant association of MnlI and ADHD (OR = 1.19; 95%
confidence interval 1.03–1.38; Faraone et al., 2005).
Previous studies reported decreased (Gilbert et al., 2006; Winsberg & Comings, 1999),
increased (Roman et al., 2002; Stein et al., 2005), or no effect (Langley et al., 2005; van der
Meulen et al., 2005) of DAT1 10 repeat allele on the methylphenidate response. There have
been fewer studies with other genes; one study reported that participants with DRD4 7R
allele needed higher MPH doses (Hamarman, Fossella, Ulger, Brimacombe, & Dermody,
2004). It has been shown that ADHD participants who were homozygous for MnlI T allele
might have a different response pattern to MPH treatment than participants who were
homozygous for the DdeI T allele (McGough et al., 2006). Participants who were
homozygous for MnlI G or DdeI C alleles were at higher risk for side effects like sleep
difficulties and abnormal movements.
The effect of certain genetic alterations in the brain function in patients with ADHD is not
clear. In fact, there is very scarce data in this field. Integrating data that are obtained from
different fields of investigation, like genetics and brain imaging are essential to have a better
understanding of the pathophysiology of complex disorders like ADHD. It has recently been
suggested that SNAP-25 polymorphism might be associated with treatment response to and
side effects of MPH (McGough et al., 2006). However, the relationship between SNAP-25
polymorphism and cerebral hemodynamic response to MPH has not been investigated. In
this study, authors’ aim was to investigate the effects of SNAP-25 genotype on the
hemodynamic response evaluated by functional near-infrared spectroscopy (fNIRS) to
interference condition in ADHD participants on or off MPH. The authors did not suggest
specific hypothesis due to the lack of previous data, therefore, the study was pilot in this
sense.
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Materials and Method
Participants
Adult ADHD Participants—A total of 15 adult ADHD participants were ascertained
from outpatient clinics of two university hospitals. Diagnoses were made according to
Diagnostic and Statistical Manual of Mental Disorders (4th ed., DSM-IV) ADHD criteria.
Wender Utah Rating Scale (WURS) was administered, using a cut-off score of 36 or higher,
which is 96% sensitive and 96% specific for detecting adult ADHD patients (Ward, Wender,
& Reimherr, 1993). Turkish translation of WURS (Oncu, Olmez, & Senturk, 2005) showed
adequate validity and reliability (Cronbach’s alpha, .88). To be diagnosed as adult ADHD,
an individual must have (a) more than six current inattention or hyperactivity/impulsivity
symptoms; (b) WURS score greater than 36 and a cut-off score validated by Ward et al.
(1993) and Oncu et al. (2005); (c) onset of symptoms before the age of 7 as confirmed by
the parental interviews, whenever possible. The authors screened all participants for current
and lifetime psychosis, schizophrenia, major depression, substance dependence (other than
smoking), and bipolar affective disorder by the corresponding structural clinical interview
for DSM-IV diagnosis (SCID-I; First, Spitzer, Gibbon, & Williams, 1996) modules. One
ADHD participant had current anxiety disorder (social phobia) and three participants had a
lifetime history of major depression. None of them had a history of documented or
suggested medical or neurological conditions. None of them had antisocial personality
disorder symptoms. Three patients, who were currently on medication, were asked to omit a
regular regime of MPH medication for a minimum of 24 hr (at least six half-lives; Gualtieri
et al., 1982) before assessment.
Pediatric ADHD Participants—Pediatric participants included 16 children with ADHD.
Six of them had other comorbid conditions including anxiety disorder, elimination disorders,
depression, and conduct disorder. ADHD, anxiety disorder, conduct disorder, and depression
diagnoses were based on DSM-IV criteria and made by the first author, using K-SADS-PL
semistructured interview (Kaufman et al., 1997). All participants were recruited from the
general outpatient clinic of a pediatric hospital. Inclusion criteria for pediatric patients
included a diagnosis of ADHD, combined type per DSM-IV criteria, being drug-naïve, and
age between 7 and 14. Exclusion criteria were the history of neurological disorders or head
trauma resulting in unconsciousness longer than 30 min and a positive history of
psychotropic drug use. Informed consent was obtained from the parents before enrollment
with local ethics committee approval for inclusion in the study. The parents could select to
opt out of the study at any time but none of the parents refused to participate or continue. All
ADHD participants had unremarkable medical history. All patients were diagnosed for the
first time and had never been evaluated for psychiatric disorders or treated with
psychopharmacological medicine.
Both pediatric and adult ADHD participants underwent two consecutive fNIRS evaluations
with an interval of 24 hr: in the first evaluation half of the participants were evaluated after a
fixed dose of 10 mg of short-acting MPH 45 min beforehand and the other half did not take
MPH. In the second evaluation the latter half was on MPH while the former was not.
fNIRS Procedures—Experiments were performed using a continuous wave near-infrared
spectroscopy device (NIROXCOPE 301) built in Biophotonics Laboratory of Bogazici
University (Akgül, Akın, & Sankur, 2006; Akın et al., 2006). The device is capable of
transmitting near-infrared light in two wavelengths (730 nm and 850 nm), which are known
to be able to penetrate through the scalp and probe the cerebral cortex (Villringer & Chance,
1997). Calculation of concentration changes in oxygenated and deoxygenated ([HbO2] and
[HHb]) is based on Beer-Lambert law. Employing four light emitting diodes (LEDs) and 10
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detectors, the device can sample 16 different volumes in the brain simultaneously. Distance
between each source and detector is 2.5 cm, which guarantees a probing depth of
approximately 2 cm from the scalp surface LEDs and detectors were placed in a rubber band
that was specially designed to fit the forehead. Figure 1 depicts an approximate placement of
the head probe on the forehead. The base of the probe is positioned to align with the
eyebrows while the midline of the probe also matches the middle of the forehead. This way,
detectors 1 through 4 scan the left dorsolateral prefrontal cortex while detectors 13 through
16 scan the right dorsolateral prefrontal cortex (DLPFC). Since Stroop task is known to
evoke a higher response bilaterally in DLPFC, we chose to concentrate our analysis to
detectors 1–4 and 13–16. [3] Sampling frequency of the device was 1.7 Hz. In this study the
authors collected data from left and right prefrontal regions with four detectors for each
region (Fp1/F3 and Fp2/F4) and then they averaged the [HbO2] and [HHb] levels (μmol)
obtained from these detectors. All four detectors in each side had one LED. [2]
Experimental Paradigm—Participants were asked to perform color-word matching
Stroop task as described earlier (Schroeter, Zysset, Kupka, Kruggel, & Cramon, 2002). They
were presented with two words one written over the other. The top one was written in ink
color whereas the below one was in white (over a black background). Participants were
asked to judge whether the word written below correctly denotes the color of the upper word
or not. If so, participants were to press the left mouse button with their finger and if not to
press the right mouse button with their middle finger. Participants were informed to perform
the task as quickly and correctly as possible. Experiment consisted of neutral, congruent,
and incongruent trials. In the neutral condition upper word consisted of four X’s (XXXX) in
ink color. In the congruent condition ink color of the upper word and the word itself were
the same whereas in incongruent condition they were different. The stimuli were presented
in a semiblocked manner. Each block consisted of six trials. Interstimulus interval within the
blocks was 4 s, and blocks were placed 20 s apart in time. The stimulus type within a block
was homogeneous (but the arrangement of correct and false stimuli might change), that is, a
block consisted only of, for instance, congruent trials, which may be correct or false. There
were five blocks of each stimulus type. The stimuli stayed on the screen until the participant
responded or disappeared at the end of 3 s in case the participant did not respond.
Experiments were performed in a silent, lightly dimmed room. Stimuli were presented via an
LCD screen that is 0.5 m away from the participants. Incorrect or absent responses on
congruent, incongruent, and neutral trials were classified as errors.
fNIRS Analysis—We employed the well-known SPM (Statistical Parametric Mapping)
approach for the analysis of the data (Ciftçi, Sankur, Kahya, & Akın, 2008; Friston, Holmes,
Poline, Frith, & Frackowiak, 1995). In the present study the authors have evaluated the
effects of MPH on brain hemodynamics during the interference condition. Thus they
calculated the difference of [HbO2] (or [HHb]) levels recorded during incongruent stimuli
(IS) and neutral stimuli (NS) (hemodynamic interference: IS ([HbO2]/[HHb]) − NS
([HbO2]/[HHb]).
Molecular Analysis
DNA extraction and analysis—With written informed consent, a blood sample was
drawn from each individual. Venous blood samples were collected in
ethylenediaminetetraacetic acid (EDTA)-containing tubes. DNA was extracted from whole
blood by salting out procedure (Miller et al., 1988).
Genotypic analysis of the SNAP-25 gene DdeI and MnlI polymorphisms—
Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP)
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assays were used to determine SNAP-25 gene (GenBank Accession Number D21267) DdeI
(rs1051312) and MnlI (rs3746544) polymorphisms.
The oligonucleotide primers used to determine the DdeI and MnlI polymorphisms within the
SNAP-25 gene were described previously (Barr et al., 2000). The primers, forward 5′-
TTCTCCTCCAAATGCTGTCG-3′ and reverse 5′-CCACCGAGGAGAGAAAATG-3′ were
used to amplify the SNAP-25 gene. PCR was performed in a 25 μl volume with 100 ng
DNA, 100 μm dNTPs, 20 pmol of each primer, 1.5 mM MgCl2, 1 × PCR buffer with
(NH4)SO4 (Fermentas, Vilnius, Lithuania), and 1 U Taq DNA polymerase (Fermentas,
Vilnius, Lithuania). Amplification was performed on an automated Thermal Cycler (Techne
Flexigene, Cambridge, UK). PCR conditions were 2 min for initial denaturation at 95°C, 35
cycles at 95°C for 45 s for denaturation, 1 min at 58°C for annealing, and 2 min at 72°C for
extension, followed by 7 min at 72°C for final extension. After amplification PCR products
were digested by restriction endonuclease 10 U DdeI (Fermentas, Vilnius, Lithuania) or 10
U MnlI (Fermentas, Vilnius, Lithuania) for 14 h at 37°C. The genotyping of the SNAP-25
gene DdeI or MnlI polymorphisms was determined by fragment separation at 120 V for 40
to 50 min on a 3.5% Agarose gel containing 0.5 μg/ml ethidium bromide. A 100-bp marker
(50-bp DNA Ladder, Fermentas) was used as a size standard for each gel lane. The gel was
visualized under UV light using a gel electrophoresis visualizing system (Vilber Lourmat).
For allele 1 (T) of DdeI the 261-bp fragment was not cut and for allele 2 (C) the fragment
was cut into two fragments of 228 bp and 33 bp. For allele 1 (T) of MnlI digest, the 261-bp
fragment was cut into two fragments of 256 bp and 5 bp but was not cut at the polymorphic
restriction site. For allele 2 (G), the 261-bp fragment was cut into 210-, 46-, and 5-bp
fragments. The 5-, 33-, and 46-bp fragments were difficult to visualize because of both its
small size and comigration with the similar size primer residue; however, detection of this
fragment was not critical in determining genotypes. Genotyping was based on independent
scoring of the results by two reviewers who were unaware of case/control status.
Data Analysis—The SPM analysis provides an average activation amplitude parameter for
each detector for each stimulus type; hence it is a univariate analysis technique. Before the
analyses, data were digitally low pass filtered with a cut-off frequency of 0.33 Hz for
removing high-frequency noise. The analyses were carried out using the general linear
model (Friston et al., 1995). The design matrix of the model consisted of stimulus onset
vectors for each type of stimulus that were convolved with the canonical hemodynamic
response function. To be able to cope with low-frequency oscillations, discrete cosine
transform functions with a minimum period of 120 s (~0.008 Hz) were generated. These
functions were added to the design matrix as nuisance variables. Consequently, regression
analysis was performed and appropriate contrast vectors were applied to get the effects of
interest. This analysis yields three numbers for each detector representing the average
response to neutral, congruent, and incongruent stimuli. The authors have contrasted the IS
to NS and set a significance threshold of p < .05 to obtain an fNIRS parameter for each
detector. Once this interference amplitude parameter is found for each detector and each
participant for off MPH, that value is then compared against the same participant’s on-MPH
parameter. Hence, we basically calculated a “difference measure” of the interference
amplitudes between the off and on MPH cases that were then used as the dependent variable
in the analysis of, for example, genotype effects in the ANOVAs. A detailed mathematical
treatise of this approach and its power over other conventional ones is given in Ciftçi et al.
(2008).
Effect of treatment on reaction time (RT) and percent errors (PE) was computed with
repeated measures analysis of variance with age and gender as covariates. Analysis of
covariance (ANCOVA) with SNAP-25 gene DdeI and MnlI polymorphisms as fixed factors
and age and gender as covariants was performed. Significant associations were followed
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with univariate tests. To compute the effect of various polymorphism combinations the
authors regrouped the MnlI and DdeI polymorphisms as T/T homozygous or others (G/G or
G/C and C/C or T/C, respectively). This resulted in four groups (1: DdeI C/C or T/C and
MnlI G/G or T/G, 2: DdeI T/T and MnlI T/T, 3: DdeI C/C or T/C MnlI T/T, 4: DdeI T/T and
MnlI G/G or T/G; Table 1). The authors also analyzed the data using these combined
subgroups.
Results
Demographic Variables
A total of 15 adult, right-handed participants with ADHD (8 men, 7 women; aged between
18 and 43, M: 26.1, SD: 7.7) and 16 right-handed pediatric ADHD participants (13 men, 3
women; aged between 7 and 14, M: 9.7, SD: 4.5) were included in the study. Gender
distribution of the pediatric and adult ADHD participants was not significantly different (x2
= 2.7; p: NS). The frequency of SNAP-25 gene DdeI and MnlI polymorphisms and the
combined groups is summarized in Table 1. Age and gender distribution were not different
among the DdeI, MnlI, and the combined polymorphism groups (F = 0.04–2.2; p > .12; x2 =
0.06–0.60, p > .44).
Behavioral Results
Main treatment effect was nonsignificant for PE (pre-treatment: M: 5.6%, SD: 7.7%;
posttreatment: M: 1.9% SD: 7.3%; F(1, 28) = .26, p = .61) and RT (pretreatment: M: 386.6
ms, SD: 206.9 ms; posttreatment: M: 348.1 ms, SD: 226.3 ms; F(1, 28) = .23, p = .63).
Change of RT and PE with treatment was also not significantly associated with genotype.
fNIRS Results
ANCOVA results indicated that SNAP-25 MnlI genotype was significantly associated with
change of right prefrontal [HbO2] (F[1, 28] = 6.8, p = .015) and left prefrontal [HHb] (F[1,
28] = 5.1, p = .033) with MPH treatment (Figure 2). Mean left prefrontal [HHb] increased
during MPH use in participants with MnlI T/G or G/G genotypes whereas it decreased in
participants with T/T genotype. The reverse pattern is true for right prefrontal [HbO2]; it
increased in the T/T and decreased in the T/G or G/G group.
SNAP-25 DdeI polymorphism was significantly associated with change of right prefrontal
[HHb] with MPH use (F[1, 30] = 13.1, p < .001; Figure 3). Right [HHb] level increased with
MPH treatment in the DdeI C/C or T/C group and decreased in the T/T group. There were
no significant associations with other hemodynamic variables.
When both DdeI and MnlI phenotypes were taken into account, we found that genotype
status was significantly associated with right [HHb] change (F[3, 30] = 6.2, p = .003).
Pairwise comparisons revealed that participants with [DdeI C/C or T/C and MnlI G/G or T/
G] genotype had significantly different right [HHb] change when compared with
participants with [DdeI T/T and MnlI T/T] or [DdeI T/T and MnlI G/G or T/G] genotypes (p
= .005 and <.001, respectively; Figure 4). While mean right HHb increased with MPH use in
the former group, it decreased in the latter groups (Table 1).
Pairwise comparisons revealed that participants with [DdeI T/T and MnlI T/T] genotype had
significantly different right [HbO2] change when compared with participants with [DdeI C/
C or T/C and MnlI G/G or T/G] or [DdeI T/T and MnlI G/G or T/G] genotypes (p = .02 and .
03, respectively; Table 1).
There were no significant interaction of age and gender for any of the variables studied.
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Discussion
fNIRS is a unique method to evaluate the hemodynamic response to cognitive and other
stimuli in a continuous way by measuring the changes in oxygenated hemoglobin and
deoxyhemoglobin levels in particularly prefrontal cortex (Villringer & Chance, 1997),
although it has been used extensively in other brain regions including motor, parietal, and
temporal cortices. The most significant advantages of this method include lack of radiation,
portable nature of the device, relative easiness, and low cost. The most significant
disadvantage is its low spatial resolution and cerebral penetration depth. Previous studies
have shown that increased (HbO2) levels during cognitive tasks could be measured by
fNIRS (Akgül et al., 2006; Ciftçi et al., 2008; Fallgatter & Strik, 1998; Matsuo, Watanabe,
Onodera, Kato, & Kato, 2004; Schroeter et al., 2002; [4] Toronov et al., 2001). Although
fNIRS has the mentioned advantages, this method has not been widely used in ADHD
research. One of the few studies comparing ADHD participants with healthy controls
reported that ADHD participants did not show the extended hemodynamic response in left
prefrontal region during Trail Making Test, a test that measures mental tracking and visual
attention performance, like the normal controls did (Weber, Lutschg, & Fahnenstich, 2005).
In another study the same group reported lower left-sided increase of oxygenation in the on-
MPH condition than the off-MPH condition (Weber et al., 2007). In a very recent study
Ehlis, Bähne, Jacob, Herrmann, and Fallgatter (2008) reported reduced task-related
increases in a working memory task in adults with ADHD, suggesting prefrontal dysfunction
in these participants.
Our results showed that SNAP-25 polymorphisms were significantly associated with right
(HbO2) and bilateral (HHb) changes with MPH use. Participants with SNAP-25 DdeI T/T
genotype had decreased right (HHb) when on MPH while right (HHb) levels increased with
participants with other DdeI genotypes. SNAP-25 MnlI genotype was also associated with
right (HbO2) change as well as left (HHb) change. When the combinations of these
genotypes were taken into account, we found that the participants with DdeI T/T and MnlI
T/T genotype had decreased right (HHb) with MPH use while right (HHb) increased in the
participants with DdeI T/C C/C and MnlI T/G G/G genotypes. This was in line with Barr
and associates’ (2000) finding that combination of DdeI and MnlI alleles might be
important.
Animal models of ADHD include the coloboma mouse mutant, which is the result of a
deletion in SNAP-25 gene (Hess, Collins, & Wilson, 1996). Deletion in SNAP-25 gene
might be related with impaired dopamine and serotonin release in dorsal (but not ventral)
striatum, which has important connections with the prefrontal cortex, the brain region
implicated in executive functioning (Brophy et al., 2002; Raber et al., 1997). It has been
shown that ADHD participants homozygous for MnlI T allele might have a different
response pattern to MPH treatment than participants who were homozygous for the DdeI T
allele (McGough et al., 2006). MnlI T homozygosity significantly and favorably affected
change of parent and teacher ratings with MPH treatment and DdeI T homozygosity had an
additional but smaller negative effect. Since the changes in SNAP-25 gene expression may
lead to alterations in neurotransmitter release (Wilson, 2000), the hyperactivity of the
colobama mouse responds to dextro-amphetamine better than MPH. The result of the former
pharmacogenomcis study indicates that SNAP-25 gene polymorphisms may also be
associated with treatment response and side effects of MPH treatment (McGough et al.,
2006).
It can be speculated that our finding of association between SNAP-25 genotype and
prefrontal hemodynamic changes with MPH might be related with different neurotransmitter
release patterns of participants with different polymorphisms. We found that MnlI T
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homozygous participants did not show the brain hemodynamics variability with MPH use.
Although we did not collect data on treatment response, it can be speculated that this lack of
hemodynamic change with MPH treatment may be related with less favorable treatment
response reported by other researchers (McGough et al., 2006). On the other hand,
participants with the combination of MnlI and DdeI T homozygosity showed significantly
different patterns of right prefrontal (HHb) change with MPH when compared with
participants with DdeI T/C C/C and MnlI T/G G/G genotypes, which suggested differential
medication response in these two groups. Again, it must be kept in mind that we did not
evaluate the effectiveness of MPH treatment.
What does the change in (HHb) or (HbO2) mean? Brain activation causes increased cerebral
blood flow, but not all of this oxygenized blood is used, therefore (HbO2) increases and
(HHb) decreases during sustained activation (Villringer & Chance, 1997). We found that
SNAP-25 gene DdeI and MnlI polymorphisms were particularly associated with change of
(HHb) with treatment. Schroeter and associates (2002) reported that (HbO2) concentration
increased and (HHb) concentration decreased more during incongruent trials specifically
over lateral prefrontal cortex. In the present study, we did not compare hemodynamic
changes during incongruent and neutral trials but investigated the effects of methylphenidate
on the difference between these two conditions. Nevertheless, following those authors, it can
be suggested that higher (HbO2) and lower (HHb) may be related with neurovascular
coupling and that increased blood flow efficiently carried (HHb) from the activated brain
regions (Schroeter et al., 2002). Right prefrontal (HHb) of participants with T/T
polymorphisms did not increase with MPH, suggesting that neurovascular coupling was
differentially affected by genotype.
Our findings indicated prominently right-sided differences, which is consistent with
previous imaging studies that reported right-sided abnormalities in ADHD participants
(Seidman et al., 2005).
The findings reported in this study must be interpreted with caution due to certain
limitations. First, we did not investigate the interaction of different polymorphisms since the
sample size was not adequate for that analysis. Second, the reported changes in the
prefrontal cortex could reflect changes in other brain regions, like basal ganglia, which could
not be evaluated with fNIRS. In this study we evaluated the effect of a single administration
of short-acting MPH. Thus, we did not have data on the symptomatic/behavioral response to
MPH, and we could not group the patients as responders or nonresponders. We did not use a
double blind placebo controlled protocol; thus in the present study it was not possible to
discern placebo effect completely. We did not evaluate the effect of comorbidity and this
might be a limitation. All patients had combined type ADHD; therefore, these results may
not be valid for other ADHD types. The age range was very broad; however, we used each
participant as its own control and also controlled the effects of age and gender statistically.
Besides, mean age of each genotype subgroup was not significantly different. We could not
control the effect of symptom severity since we included both adult and pediatric
participants and we did not have comparable symptom ratings for these groups. It can be
suggested that adult ADHD participants had relatively low severity of symptoms because
they were not diagnosed and treated for many years. However, this may not be true for
ADHD that has very recently been diagnosed in adults in Turkey. We did not find any
association between genotype and treatment with behavioral performance. This might be
due to good performance of the participants even in the off-medication condition.
Considering all these limitations, confirmation of the present results is clearly necessary.
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Nevertheless, our results suggested that SNAP-25 gene DdeI and MnlI polymorphisms
might be associated with MPH-related changes in brain hemodynamics in ADHD
participants.
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Figure 1.
Location of the sources and detectors on the forehead and their approximate probed volumes
on the cortex.
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Figure 2.
Change of left and right HHb with methylphenidate. Effect of SNAP-25 MnlI
polymorphism. Y-axis: HHb during Stroop neutral stimuli minus HHb during Stroop
incongruent stimuli.
Öner et al. Page 14
J Atten Disord. Author manuscript; available in PMC 2011 December 2.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3.
Change of left and right HHb with methylphenidate. Effect of SNAP-25 DdeI
polymorphism. Y-axis: HHb during Stroop neutral stimuli minus HHb during Stroop
incongruent stimuli.
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Figure 4.
Change of left and right HHb with methylphenidate. Effect of SNAP-25 MnlI and DdeI
polymorphisms combined. Y-axis: HHb during Stroop neutral stimuli minus HHb during
Stroop incongruent stimuli.
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